Trials / Completed
CompletedNCT04103060
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Dermavant Sciences GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cerdulatinib 0.37% gel | Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks |
| DRUG | Vehicle gel | Vehicle gel applied topically twice daily for 6 weeks |
Timeline
- Start date
- 2019-09-27
- Primary completion
- 2020-11-03
- Completion
- 2020-11-03
- First posted
- 2019-09-25
- Last updated
- 2020-11-24
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04103060. Inclusion in this directory is not an endorsement.